Navigation Links
Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation
Date:2/23/2011

s disease, but these data are extremely exciting, especially for people with the G551D mutation and their families. The results also offer significant hope that a similar approach to treatment may help the majority of patients living with CF."

The Phase 3 data support Vertex's plan to submit a New Drug Application for VX-770 to the U.S. Food and Drug Administration (FDA) in the second half of 2011. Generally, the FDA takes between 6 and 12 months to review and rule on a drug application.

"The Cystic Fibrosis Foundation has played an instrumental role in our more than 10-year effort to discover and develop potential new CF medicines such as VX-770," said Matthew W. Emmens, chairman, president and CEO of Vertex. "The data announced today reflect a significant investment of time, dollars and scientific expertise from both Vertex and the CF Foundation, and we look forward to working closely with the Foundation as we seek to bring VX-770 to people with CF."

Said Preston W. Campbell III, M.D., executive vice president for medical affairs of the Cystic Fibrosis Foundation: "As a physician who has treated CF patients for many years, the VX-770 results are more than just numbers -- they represent hope." He added, "It's not surprising that patients felt better on the drug because of the magnitude of lung function improvement and weight gain. These are important clinical outcomes, and the fact they were maintained through 48 weeks is very encouraging."

Developing a therapy for individuals with the most common CF mutation, Delta F508, remains a top priority of the CF Foundation. A Phase 2 trial for those with Delta F508 is underway to test VX-770 in combination with a drug known as VX-809. Like VX-770, VX-809 resulted from discovery efforts between Vertex and the CF Foundation. Laboratory studies suggest a combination of the two drugs may be more beneficial than either one alone. Results of this clinical trial are expected later this year.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... Prostate Vanguard, an awareness campaign to educate men about ... needle biopsies of the prostate. Annually, a million ... gland through the rectum. Multi-parametric MRI (MP-MRI) of the ... prostate cancer (CSPC). Men need to be fully ...
(Date:9/17/2014)... Sept. 17, 2014  Rebiotix Inc. announced this morning that ... product candidate, RBX2660 (microbiota suspension) will be presented in two ... in Philadelphia from October 8-12. ... the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety ...
(Date:9/17/2014)... SAN JOSE, Calif. , Sept. 17, 2014 /PRNewswire-iReach/ ... a laureate of The Tech Awards 2014, one of ... humanity and spark global change. The Tech Awards, a signature ... Applied Materials, Inc., selected Gradian as one of two laureates ... http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips hospitals around ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3
... New data presented at annual American Transplant Congress ... R. Carreno, MD, and colleagues in,the Departments of ... -,Lawrence Miller School of Medicine have corroborated the ... in recipients of,kidney transplants using a regular laboratory ...
... 2 Medarex, Inc.,(Nasdaq: MEDX ) ... Phase 1,study of MDX-1106 (ONO-4538: development code ... anti-PD-1 antibody. Data presented from patients with,recurrent ... the safety,tolerability and pharmacokinetic profile of single-dose ...
Cached Medicine Technology:University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4
(Date:9/17/2014)... reduce the need for invasive biopsies in patients suffering ... In a new study, researchers developed a math model ... inflammation to interstitial fibrosis, scarring in the kidney ... the only existing way to reach a definitive diagnosis ... could also be used to monitor the effectiveness of ...
(Date:9/17/2014)... shown that most 18-month-olds learn an average of two ... known about how children process information to learn new ... a new study, a University of Missouri researcher has ... and a limit exists as to how many words ... parents enhance their children,s vocabularies and assist speech-language professionals ...
(Date:9/17/2014)... Missouri (PRWEB) September 17, 2014 Mercy ... week, hoisting the building’s final beam into place. Sister ... it made its ascent. (Photos and video of the ... the beam, available here: http://bit.ly/MercyVirtual .) , “The ... high quality medical care to thousands of patients regardless ...
(Date:9/17/2014)... 2014 In a country where 77% ... a regular basis, how can Americans find healthy and ... Hyland’s Stress Challenge , a 5-day interactive journey to ... life. From September 29th – October 3rd, the ... relating to specific topics that promote natural solutions for ...
(Date:9/17/2014)... September 17, 2014 Ticket Down ... tickets for all tour dates. The Disney on ... characters around the United States and across the world to ... year, the 2013 cult-hit Frozen will be showcased in the ... shows, Frozen on Ice. The show will kicked off at ...
Breaking Medicine News(10 mins):Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Babies learn words differently as they age, researcher finds 2Health News:Mercy Tops Out World's First Virtual Care Center 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Frozen on Ice Tickets: Ticket Down Slashes Ticket Prices in Atlanta, Uniondale, Richmond, Philadelphia, Hershey, Nashville, Hampton, Brooklyn, Chicago, Boston & St. Louis 2
... it,s no better than standard treatment, one expert says, ... the indigestion and heartburn that bother many women as ... Indigestion is common during pregnancy, with up to 80 ... reflux, belching and bloating. Symptoms tend to worsen over ...
... - Europe Cosmetiques and Probiox announced today that both ... respect to oxidative stress profiling. Under this agreement, Europe ... and Mexico. , According to Manon Pilon, Founder President ... the leader in the Medical SPA industry, and is ...
... PEMBROKE, Bermuda, June 9 Allied World ... Assurance Company,Holdings, Ltd (NYSE: AWH ), today ... product offered in the United States. The,complimentary service, called ... crisis management resources in the,event of a catastrophe. , ...
... Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... trial of sodium oxybate (JZP-6) for the treatment of ... Professional Sleep Societies (APSS) 2009 Annual Meeting in Seattle, ... (EULAR) Congress in Copenhagen, Denmark. , , Following ...
... Programs Designed to Address High Risks for New Dialysis Patients ... , DENVER, June 9 DaVita Inc. (NYSE: ... those diagnosed with chronic kidney disease (CKD), today commended Kidney ... Kidney Care (PEAK) campaign. Kidney Care Partners - a ...
... New techniques bring equivalent results without the potential dangers, ... Researchers say they,ve developed new techniques for reducing ... disease. , The use of these radiation-lowering strategies did ... computed tomography angiography (CCTA), an increasingly popular weapon in ...
Cached Medicine News:Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:"Alliance between Europe Cosmetiques and Probiox brings new oxydative stress profiling technologies to North America" 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 2Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 3Health News:Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 4Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3Health News:Reduced-Radiation Heart Scans Don't Compromise on Quality 2
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Standard Trephine...
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Long Handled Trephine...
Medicine Products: